hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06315673 id: STUDY00024562 briefTitle: Digital Assessment of Speech and Fine Motor Control in ALS overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-03-30 date: 2027-03-30 date: 2024-03-18 date: 2024-03-18 name: Milton S. Hershey Medical Center class: OTHER name: BioSensics briefSummary: This is a single-session, case-control study that incorporates digital tools for assessing speech and motor function in motor neuron disease. Patients with motor neuron disease (including amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS), and progressive muscular atrophy (PMA)) and age-matched healthy controls will be enrolled. Subjects will complete a speech and handwriting assessment during the study visit on a tablet computer (BioSensics LLC, Newton, MA). We will explore whether these digital biomarkers are sensitive to functional disease severity as reported by the ALS Functional Rating Scale - Revised (ALFRS-R) \[1\]. We will also compare assessment data between the patient and control groups. conditions: Amyotrophic Lateral Sclerosis conditions: Primary Lateral Sclerosis conditions: Progressive Muscular Atrophy studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 50 type: ESTIMATED name: Digital Speech and Handwriting Assessment measure: Speaking rate during a standardized passage measure: Residual on spiral tracing task measure: ALS Functional Rating Scale- Revised (ALSFRS-R) measure: Forced vital capacity (FVC) measure: Upper motor neuron function measure: Strength testing sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06315660 id: P-2021-627 briefTitle: VR Based Therapy to Treat Anxiety in Dual Diagnosis overallStatus: NOT_YET_RECRUITING date: 2024-11 date: 2026-04 date: 2026-04 date: 2024-03-18 date: 2024-03-18 name: Mental Health Centre Sct. Hans class: OTHER_GOV briefSummary: Dual diagnosis refers to patients with both severe mental illness and substance abuse. Dual diagnosis is therefore a challenging condition to treat, and the group typically represents the most vulnerable individuals in society. Historically, research on dual diagnosis has been underprioritized, and thus, we still do not know enough about how to best assist this vulnerable group.
However, new studies indicate that virtual reality programs can reduce anxiety in patients with psychotic disorders. They achieve this by providing access to a virtual therapist and lifelike environments where patients can challenge their thoughts about the dangers of navigating the world. For both psychotic disorders and substance abuse, we know that anxiety often plays a role in the clinical picture. Therefore, anxiety almost always has an impact on dual diagnosis patients, where it is crucial in maintaining substance abuse and functional impairment. Despite this, anxiety is rarely a focus in existing treatment options, as it is too resource-intensive in addition to an already intensive treatment process.
This study investigates whether the resource barrier can be overcome and whether hospitalized dual diagnosis patients can experience reduced anxiety, fewer relapses, and better outcomes after discharge when their anxiety is treated through partially automated virtual reality therapy. conditions: Dual Diagnosis conditions: Psychosis conditions: Agoraphobia conditions: Social Anxiety Disorder conditions: Substance Use Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The study is a parallel group, investigator initiated, pragmatic, assessor-blinded, 1:1 randomized, clinical feasibility trial. primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: When a participant is randomized to TAU+VR, the senior researcher reveals the allocation to the assigned clinician via secure e-mail. The assigned clinician then schedules the eight therapy sessions with the participant who is thus unblinded to their treatment allocation. If the participant is randomized to TAU, the assigned clinician will inform the participant as soon as possible. The researchers collecting data from the patient and the researchers performing data analysis remain blinded. There are no circumstances wherein unblinding of outcome assessors or data analysists is permissible. whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 30 type: ESTIMATED name: Cognitive Miljeu Therapy name: Virtual Reality based CBT for Anxiety measure: Oxford Agoraphobic Avoidance Scale measure: Client Satisfaction Questionnaire measure: Systems Useability Scale measure: Timeline Followback measure: The Six-item Positive and Negative Symptom Syndrome Scale measure: The Social Functioning Scale measure: The Questionnaire about the Process of Recovery sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06315647 id: Difficult CBD cannulation briefTitle: Comparison Between Different Techniques in Difficult CBD Cannulation overallStatus: COMPLETED date: 2019-12-01 date: 2023-01-19 date: 2023-11-20 date: 2024-03-18 date: 2024-03-18 name: Menoufia University class: OTHER briefSummary: This study aims to compare the efficacy and outcomes between double guidewire technique (DGT), trans pancreatic sphincterotomy (TPS) as well as precut and fistulotomy techniques in ERCP in patients defined as having difficult biliary cannulation. conditions: ERCP, Difficult CBD Cannulation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: SINGLE whoMasked: INVESTIGATOR count: 150 type: ACTUAL name: DGT vs TPS vs Precut and fistulotomy in Difficult CBD cannulation measure: Comparative Study Between Different Interventional Techniques for Difficult Common Bile Duct Cannulation In Endoscopic Retrograde Cholangio-pancreatography sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National liver Institute city: Shibīn Al Kawm state: Menofia zip: 32951 country: Egypt lat: 30.55258 lon: 31.00904 hasResults: False
nctId: NCT06315634 id: AP210330102 briefTitle: Intrathecal Dexmedetomidine vs Midazolame overallStatus: COMPLETED date: 2021-03-15 date: 2022-03-10 date: 2022-03-10 date: 2024-03-18 date: 2024-03-18 name: National Cancer Institute, Egypt class: OTHER briefSummary: Prospective Randomized Controlled Clinical Trial to Compare Intrathecal Dexmedetomidine Versus Midazolame in Orthopedic Cancer Surgeries conditions: Postoperative Pain studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 75 type: ACTUAL name: Dexmedetomidine name: Midazolam name: Bupivacain measure: Duration of sensory block measure: Incidence of vomiting occurrence measure: Sedation measure: Change in mean arterial blood pressure measure: Duration of motor block measure: Change in heart rate sex: ALL minimumAge: 20 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National cancer institute city: Cairo zip: 11796 country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06315621 id: 36124 briefTitle: Accuracy of Conventional Impression Versus Intraoral Scanner in Capturing Three Different Nasal Defects overallStatus: COMPLETED date: 2024-02-01 date: 2024-02-20 date: 2024-02-20 date: 2024-03-18 date: 2024-03-18 name: Cairo University class: OTHER briefSummary: For all participants, a conventional facial impression will be done using silicone material then poured and scanned using a desktop scanner which represented the control group (Group 1).
STL files of the facial scans and scanned cast obtained from the impression will be exported and saved to be used later for outcome assessment. conditions: Nasal Defect studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 15 type: ACTUAL name: Scanning using intraoral scanner with markers name: Scanning using intraoral scanner without markers name: Physical Impression measure: Dimensional accuracy of intraoral scanners sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Cairo University city: Cairo zip: 11865 country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06315608 id: MRG24ALS briefTitle: MRG-001 in Patients With Amyotrophic Lateral Sclerosis overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2024-11-01 date: 2024-12-01 date: 2024-03-18 date: 2024-03-18 name: MedRegen LLC class: INDUSTRY briefSummary: The proposed study is an Open-Label, Single-Dose Study to Assess the Safety, and Pharmacodynamics (PD) signals of MRG-001 in Patients with Amyotrophic Lateral Sclerosis (ALS). MRG-001 will be administered subcutaneously 3 times per week for 2 weeks. This cycle will be repeated for 3 months. In total, patients are expected to receive 18 injections over the span of 3 months. conditions: Amyotrophic Lateral Sclerosis conditions: Lou Gehrig Disease conditions: Motor Neuron Disease conditions: Motor Neuron Atrophy studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: MRG-001 measure: Assessment of Treatment-Emergent Adverse Events measure: Stem Cell Mobilization measure: Regulatory T-cell Mobilization measure: Change in Disease Progression sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06315595 id: 15-003511 id: NCI-2024-01895 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: 15-003511 type: OTHER domain: Mayo Clinic Institutional Review Board id: P30CA015083 type: NIH link: https://reporter.nih.gov/quickSearch/P30CA015083 id: R01EB031790 type: NIH link: https://reporter.nih.gov/quickSearch/R01EB031790 briefTitle: Improvements in Dynamic Contrast-Enhanced MR Angiography and Perfusion overallStatus: RECRUITING date: 2015-09-30 date: 2030-09-30 date: 2030-09-30 date: 2024-03-18 date: 2024-03-19 name: Mayo Clinic class: OTHER name: National Cancer Institute (NCI) name: National Institute for Biomedical Imaging and Bioengineering (NIBIB) briefSummary: This study evaluates contrast-enhanced MR angiography and contrast-enhanced MR perfusion imaging for the visualization of blood vessels and enhancing tissues with better spatial detail and improved temporal fidelity compared to current methods. conditions: Prostate Neoplasm studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 300 type: ESTIMATED name: Non-Interventional Study measure: Improved performance in contrast-enhanced magnetic resonance imaging (MRI) as used for angiography and perfusion sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic in Arizona status: ACTIVE_NOT_RECRUITING city: Scottsdale state: Arizona zip: 85259 country: United States lat: 33.50921 lon: -111.89903 facility: Mayo Clinic in Rochester status: RECRUITING city: Rochester state: Minnesota zip: 55905 country: United States name: Clinical Trials Referral Office role: CONTACT phone: 855-776-0015 name: Stephen J. Riederer, Ph.D. role: PRINCIPAL_INVESTIGATOR lat: 44.02163 lon: -92.4699 hasResults: False
nctId: NCT06315582 id: STU00220487 briefTitle: Surgical Approach to Uterine Septum overallStatus: RECRUITING date: 2024-03-11 date: 2025-08-26 date: 2026-02-26 date: 2024-03-18 date: 2024-03-18 name: Northwestern University class: OTHER briefSummary: The objective of this study is to determine if the use of scissors without electrosurgery is superior to bipolar electrosurgery for resection of uterine septum. The investigators will be comparing procedure-level variables such as operative time, complications, and need for additional procedures. conditions: Uterine Septum conditions: Surgical Complication conditions: Septum; Uterus conditions: Treatment Side Effects conditions: Treatment studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized single blinded study primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Participants will be randomized using www.randomizer.org algorithm. They will be assigned to arm in the operating room where they will get that intervention. When they get to Post Anesthesia Care Unit, they will be unblinded. Surgeon will be blinded until patient is in operating room and envelope with randomization is opened. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 40 type: ESTIMATED name: Removal of uterine septum with hysteroscopic scissors without electrosurgery. name: Hysteroscopic septoplasty utilizing bipolar electrosurgery measure: Procedure-level variables: operative time hysteroscopic septoplasty measure: Procedure-level variables: Surgical Cost measure: Procedure-level variables: Fluid deficit measure: Resolution of uterine septum measure: Compare adverse events measure: Comparing patient recovery and satisfaction sex: FEMALE minimumAge: 22 Years maximumAge: 44 Years stdAges: ADULT facility: Northwestern Medicine Prentice Women's Hospital status: RECRUITING city: Chicago state: Illinois zip: 60611 country: United States name: Milad Madgy, MD role: CONTACT email: mmilad@nm.org lat: 41.85003 lon: -87.65005 hasResults: False
nctId: NCT06315569 id: KY20242030-C-1 briefTitle: A Multicentre Clinical Study on the Correlation Between Exercise and Hyperuricemia overallStatus: RECRUITING date: 2024-01-17 date: 2024-06-01 date: 2024-11-01 date: 2024-03-18 date: 2024-03-18 name: Xijing Hospital class: OTHER name: Air Force 986 Hospital briefSummary: This project is a multi-center clinical study on the correlation between exercise and hyperuricemia. The purpose is to explore the correlation between exercise and hyperuricemia, find out the metabolic rule of uric acid after exercise, and provide scientific evidence and clinical guidance for how to exercise scientifically and reasonably in patients with hyperuricemia. This trial is a multicenter, prospective, randomized controlled clinical trial with 100 participants. Inclusion criteria: 1. Patients with hyperuricemia (fasting uric acid \> 420μmol/L twice on different days); 2. Men aged between 18 and 35; 3. Able to complete baseline fitness test (3000m run time less than 14 minutes); 4. Fully informed consent, signed informed consent exclusion criteria: 1. Heart, liver and kidney insufficiency; 2. Patients with malignant tumor, thyroid disease, systemic lupus erythematosus, myeloma, lipodystrophy, diabetes mellitus; 3. Patients with secondary hyperuricemia caused by medicine or other diseases; 4. People who take uric acid lowering drugs; 5. People with related motor dysfunction or other factors that can easily cause discomfort after exercise 6. Those with mental disorders or communication disorders, and those who do not cooperate during the experiment A total of 100 subjects were included according to the scheduling criteria. SPSS23.0 software was used to generate a random number table, and random numbers were calculated according to 1: The results of the groups were sealed in opaque envelopes, and the envelopes were kept by A third party responsible for randomization. According to the contents of the envelopes, the subjects were divided into group A, which exercised for 24 hours after 3000m exercise, and group B, which exercised for 48 hours after 3000m exercise. During the 48-hour observation period after each exercise, the changes of uric acid after exercise were explored. To provide scientific evidence and clinical guidance for patients with hyperuricemia how to exercise scientifically and rationally.
Patients must meet all inclusion and exclusion criteria to be eligible to participate in the study. After determining patients' eligibility for the study, the researcher should fully explain the nature, purpose, risks and benefits of the study to the subjects before the study, and assure the patients that they have the right to withdraw at any time after agreeing to participate in the study, and the subjects should sign a written informed consent after fully considering and agreeing to participate in the study. The process of obtaining informed consent should be correctly recorded in all case report forms in this study.
Within 48 hours after each 3000m exercise, the subjects' blood uric acid was detected immediately after exercise (within 5 minutes), 1 hour, 2 hours, 3 hours, 12 hours, 24 hours, 36 hours, 48 hours. Blood uric acid, blood biochemistry, blood routine, urine routine, urine uric acid and other information were collected again 24 hours after intervention.
From January 2024 to February 2024, we plan to draft clinical study protocols, investigator manuals, case reports, informed consent forms and other documents, and submit them to the Ethics Committee of the research sponsor for review and approval; February 2024 - March 2024: Complete the training of all researchers and officially start the research; March 2024 - August 2024: Participants were enrolled for the experiment; August 2024 - November 2024: collate and collect data, conduct statistical analysis, and confirm research results conditions: Hyperuricemia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 100 type: ESTIMATED name: Run 3000 meters measure: Uric acid metabolism in patients with hyperuricemia after exercise sex: MALE minimumAge: 18 Years maximumAge: 35 Years stdAges: ADULT facility: Xijing Hospital status: RECRUITING city: Xi'an state: Shanxi zip: 710032 country: China name: XiangLiang Meng role: CONTACT phone: +8613730192056 email: 997815173@qq.com lat: 34.25833 lon: 108.92861 hasResults: False
nctId: NCT06315556 id: 22539 briefTitle: An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK) overallStatus: RECRUITING date: 2024-03-05 date: 2027-03-31 date: 2027-04-30 date: 2024-03-18 date: 2024-04-12 name: Bayer class: INDUSTRY briefSummary: This is an observational study in which only data from babies with retinopathy of prematurity (ROP) who are being treated with aflibercept (Eylea) in prefilled syringe (PFS) using a paediatric dosing device (PDD) are collected and studied.
ROP is a condition that affects the eyes of preterm babies. It occurs when the baby's retina, the part of the eye that senses light, does not develop normally. This may result in vision problems, including blindness, if left untreated. Preterm babies are born before 37 weeks of pregnancy. ROP is more likely to develop in babies who are born before 32 weeks of pregnancy or weigh less than 1.5 kilograms at birth.
In this study only available data from preterm babies born during the study period are collected. No visits or tests are required as part of this study. conditions: Retinopathy of Prematurity conditions: Preterm Infants studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 200 type: ESTIMATED name: Aflibercept (Eylea) measure: Number of participants treated with Eylea PFS+PDD upon completion of 1- or 3-years following market introduction measure: Summary of patient characteristics reported as number of participants with different categories measure: Summary of maternal factors reported as number of participants with different categories measure: Summary of comorbidities reported as number of participants with different categories measure: Summary of clinical condition and resource utilization reported as number of participants with different categories measure: Summary of clinical condition and resource utilization reported as days measure: Summary of outcomes of the premature infants reported as number of participants with different categories measure: Summary of ocular disease and treatment reported as number of participants with different categories sex: ALL maximumAge: 1 Year stdAges: CHILD facility: Many locations status: RECRUITING city: Multiple Locations country: United Kingdom hasResults: False
nctId: NCT06315543 id: KY20222255-F-1 briefTitle: A Multicentre Clinical Study on the Correlation Between Drinking Water and Hyperuricemia overallStatus: RECRUITING date: 2024-01-15 date: 2024-06-01 date: 2024-11-01 date: 2024-03-18 date: 2024-03-18 name: Xijing Hospital class: OTHER name: Air Force 986 Hospital briefSummary: The name of this study is a multicentre clinical study on the correlation between drinking water and hyperuricemia. The purpose of this study is to clarify the correlation between drinking water and hyperuricemia. To explore the clinical effect of reducing uric acid by drinking water, and provide scientific evidence and clinical guidance for reducing uric acid by drinking water. The study design was a multicenter, prospective, randomized controlled clinical trial with a total of 88 participants. 1. Inclusion criteria: patients with hyperuricemia (fasting uric acid between 420-540μmol/L twice on different days and no drug treatment); Aged 18-65 years; Less than 1500mL of daily water intake recommended by the minimum dietary guidelines (assessed by dietary review combined with water diaries); Fully informed consent. Sign informed consent. 2. Exclusion criteria: patients with heart, liver and renal insufficiency; Patients with malignant tumor, thyroid disease, systemic lupus erythematosus, myeloma, lipodystrophy, polycystic ovary syndrome, diabetes mellitus; Patients with secondary hyperuricemia caused by medicine or other diseases; People who have gastrointestinal discomfort or have a history of gastrointestinal surgery, or other people who are not suitable for drinking more water; Patients with mental disorders or communication disorders, and those who did not cooperate during the experiment. A total of 88 subjects were included according to the exclusion criteria. SPSS26.0 software was used to generate a random number table, and random numbers were calculated according to 1: The results of the groups were sealed in opaque envelopes, and the envelopes were kept by A third party responsible for randomization. The subjects were divided into two groups according to the contents of the envelopes: A constant drinking water observation group (maintaining the original drinking water volume) and B adequate drinking water intervention group (drinking an additional 1650mL of water per day (3 bottles of 550mL bottled water) on the basis of the original drinking water volume). During the 2-week observation period, the effects of constant drinking water and sufficient drinking water on blood uric acid, 24 h uric acid determination, urine osmotic pressure and other indicators were evaluated, and the effectiveness of sufficient drinking water in reducing blood uric acid was determined, and the applicable population was explored.